Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 11,75 € (+168,26 %). La mediana es de 10,73 € (+144,98 %).
| Comprar |
14 |
| Mantener |
19 |
| Vender |
4 |
Noticias Ir al feed de noticias
Court backs X in trademark dispute, allows Bluebird to keep bird logo and "to tweet"
A Delaware court preliminarily found that X (formerly Twitter) is likely to retain the trademark rights in a later main proceeding, and in doing so has already protected the company against further infringements. At the same time, the start-up Bluebird may continue to use its feathered logo and the verb "to tweet" for sending messages. Judge Colm Connolly justified the injunction by saying Bluebird infringed and diluted the marks, but the court sees signs that X stopped earlier use. The main trademark trial will decide the final rights. » Más en faz.net
Datos financieros de la empresa
| (EUR) | marzo de 2025 | |
|---|---|---|
| Ingresos | 35,78 M | - |
| Beneficio bruto | 24,47 M | - |
| Beneficio neto | -26,87 M | - |
| EBITDA | -7,1 M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 41,78 M € |
Número de acciones | 9,79 M |
Máximo/mínimo de 52 semanas | 24,55 € - 2,75 € |
| Dividendos | No |
Beta | 0,37 |
Ratio P/E | -0,20 |
Ratio PEG | 0,00 |
Ratio P/B | -1,53 |
Ratio P/S | 0,58 |
Perfil de la empresa
| Nombre | Bluebird Bio Aktie |
| CEO | Andrew Obenshain |
| Empleados | 248 |
Descubrir activos
Los accionistas de Bluebird Bio Aktie también invierten en los siguientes activos